- 1、本文档共25页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
《中国丙肝》ppt课件
R2:一项亚洲基因1型慢丙肝的独立研究中,200例慢丙肝患者分别接受聚乙二醇干扰素α-2a 180μg联合利巴韦林1000-1200mg治疗24周、48周,停药随访24周 R3:的研究设计:国际多中心、随机对照研究中,1121例患者随机接受聚乙二醇干扰素α-2a180μg/周联合利巴韦林(1000/1200mg)、干扰素a-2b 3MIU联合利巴韦林(1000/1200mg)治疗48周,随访24周 R4:基因lb型或者基线高病毒载量初治慢性丙型肝炎患者438 例, 给予聚乙二醇干扰素a-2aa180 ug/w联合利巴韦林抗病毒治疗, 治疗疗程由治疗12 周时病毒学应答情况决定。治疗12 周H CV R N A 15IU/ m L 患者给予总共48 周疗程治疗. R2 Recommended treatment for hepatitisCvirus genotype 1 (HCV-1) patients is PEGinterferon plus ribavirin for 48 weeks. We assessed whether treatment duration of 24 weeks is as effective as standard treatment in HCV-1 patients with a rapid virological response (RVR; seronegative for hepatitis C virus [HCV] RNA at 4 weeks). Two hundred HCV-1 patients were randomized (1:1) to either 24 or 48 weeks of PEGinterferon-alpha-2a (180 g/week) and ribavirin (1000-1200 mg/day) with a 24-week follow-up. The primary endpoint was a sustained virological response (SVR; seronegative for HCV RNA at 24-week follow-up). Overall, the 48-week arm had a significantly higher SVR rate (79%) than the 24-week arm (59%, P 0.002). For 87 (43.5%) patients with an RVR, the 24-week arm had a lower SVR rate [88.9%; 95% confidence interval (CI): 80%-98%] than the 48-week arm (100%, P 0.056). For 52 patients with low baseline viremia (400,000 IU/mL) and an RVR, the 24-week arm had rates (CI) of relapse and SVR of 3.6% (3%-11%) and 96.4% (89%-103%), respectively, which were comparable to those of the 48-week arm (0% and 100%) with difference (CI) of 3.6% (7.2%-6.6%) and3.6% (14.3% to0.6%), respectively. Multivariate analysis in all patients showed that RVR was the strongest independent factor associated with an SVR, followed by treatment duration, mean weight–based exposure of ribavirin, and baseline viral load. Conclusion: HCV-1 patients derive a significantly better SVR from 48 weeks versus 24 weeks of PEGinterferon/ribavirin even if they attain an RVR. Both 24 and 48 weeks of therapy can achieve highSVRrates (96%) inHCV-1patients with low viral loads and an RVR.
您可能关注的文档
最近下载
- 传染病预防控制必修和选修答案-2024年全国疾控系统“大学习”活动.docx VIP
- 汕德卡车身控制单元NanoBCU.pdf VIP
- 力高中物理优秀课件 (2).ppt
- 无人机驾驶员高级巡检理论考试复习题库(含答案).docx
- 2024年疾控大学习国家传染病智能监测预警前置软件答案.docx VIP
- 二年级第一学期人教版二年级数学上册第八单元(数学广角搭配(一))检测卷(附答案).docx VIP
- 安宫牛黄丸培训.ppt
- 统编版小学语文三年级上册第三单元 童话王国 大单元整体学历案教案 教学设计附作业设计(基于新课标教学评一致性).docx
- 寻找红色记忆传承红色基因红色传奇传承基因主题班会PPT模板-7343.ppt VIP
- 大学英语四级考试2024年6月真题(第二套)及答案解析.pdf
文档评论(0)